Seeking Alpha

Illumina, Inc. (ILMN)

  • Oct. 21, 2013, 5:47 PM
    | 1 Comment
  • Oct. 21, 2013, 4:23 PM
    • Shares of Illumina (ILMN) are up 6.3% AH following the company's top and bottom line beat.
    • Gross margin (ex-items) comes in at 70.2%, roughly in line with Q3 2012.
    • R&D expense: $71M versus $54.1M in the same period a year ago.
    • "These results highlight another quarter of solid operational execution and record financial performance," CEO Jay Flatley says.
    • FY13 outlook: $1.75-1.77/share versus previous guidance of $1.68-1.72/share and against consensus of $1.72/share.
    | Comment!
  • Jul. 23, 2013, 4:34 PM
    More on Illumina's (ILMN) Q2: Revenue beats comfortably. Gross margin falls 420 bps on a GAAP basis but only 140 bps ex-items. R&D falls 5% while SG&A rises 29% Y/Y. CEO Jay Flatley is "very pleased" with the company's H1 financial performance. FY13 outlook: Non-GAAP EPS of $1.68-1.72 (20% revenue growth) against consensus of $1.67/ share. Shares +4.8% AH. (PR)
    | Comment!
  • Jul. 23, 2013, 4:17 PM
    Illumina (ILMN): Q2 EPS of $0.43 beats by $0.03. Revenue of $346M (+23% Y/Y) beats by $14.23M. Shares +3.7% AH. (PR)
    | Comment!
  • Jul. 12, 2013, 4:32 PM
    Celldex (CLDX +4%), Seattle Genetics (SGEN +3.2%), Ariad (ARIA +10.3%), and Pharmacylics (PCYC +6.3%) are a few more names that spiked on a report Roche is working on a bid for Alexion. On the other hand, Illumina (ILMN -1.4%) dipped lower. (previous)
    | Comment!
  • Jul. 2, 2013, 10:17 AM
    Illumina (ILMN -1.4%) slips this morning on a downgrade to Neutral on valuation at Piper Jaffray. The firm also lowered its price target to $70 from $72 a share, which, based on the chart appears to be in the a conservative call in the mid-range of where its been trading since early March.
    | 1 Comment
  • May. 10, 2013, 3:29 PM
    Shares of Illumina (ILMN +10%) ramp higher today, spiking up on heavy volume with no apparent news driving the move. Of note; short interest in the stock continues to inch higher, but days to cover has plummeted as average daily volume in the shares has nearly doubled since March, bringing it back to nearly 2M shares per day, a level it hasn't seen since January - and perhaps an indication of piquing institutional interest.
    | Comment!
  • Apr. 23, 2013, 12:56 PM
    Midday top 10 gainers: SCON +118%. MEMS +49%. CZR +29%. NFLX +24%. ARL +18%. CPLA +18%. VECO +17%. HSTM +17%. SANM +16%. ILMN +15%.
    Midday top 10 losers: CPRX -15%. IIVI -13%. UNTK -13%. ABIO -13%. CASM -10%. EFUT -9%. GASS -9%. TAX -8%. SIFY -7%. USTR -7%.
    | Comment!
  • Apr. 23, 2013, 9:27 AM
    Illumina (ILMN) moves higher in pre-trading after easily beating on its Q1 yesterday. In its conference call, the company reiterates that it expects a 2% - 4% impact as a result of sequestration, suggesting the damage will likely be limited. One of the offsetting factors management mentions is that "under the continuing resolution much of the NIH allocation was at 90% of the grant amount and so that has a potential small upside effect that could neutralize any of the downside effects from sequestration." Read more on the call here: (Earnings Call Transcript). Shares +9.3% pre-open.
    | Comment!
  • Apr. 23, 2013, 9:10 AM
    Premarket gainers: MEMS +50%. SCON +46%. NFLX +24%. VECO +14%. COH +12%. ILMN +10%. ARMH +9%. CZR +8%. STM +6%. AMRN +6%.
    Losers: IRWD -10%. RSH -7%. IOC -6%.
    | Comment!
  • Apr. 22, 2013, 5:54 PM
    After-hours top gainers, as of 5:15 p.m.: VECO +9%. SWFT +6%. ILMN +4%. WIT +4%. QCCO +3%.
    After-hours top losers: BEAT -11%. RCII -6%. HOV -5%. RFMD -5%. REGI -4%.
    | 1 Comment
  • Apr. 22, 2013, 5:10 PM
    More on Illumina (ILMN): The stock is trading higher in the post session as its Q1 easily beats across the board on a 21% jump in revenue Y/Y. The company swung to a net loss for the quarter however, after taking nearly a $107M loss related to its unfavorable verdict in its patent litigation with Syntrix Biosystems. R&D and SG&A expenses were both higher as a percentage of revenue, while margins were relatively flat compared to the prior year. Shares +4.3% AH.
    | Comment!
  • Apr. 22, 2013, 4:20 PM
    Illumina (ILMN): Q1 EPS of $0.46 beats by $0.07. Revenue of $331M beats by $20.36M. Shares +4.3% AH. (PR)
    | Comment!
  • Mar. 21, 2013, 4:33 PM
    Illumina (ILMN) wins a favorable judgment in its patent litigation against Life Technologies (LIFE), with the court saying that its sequencing systems do not infringe on LIFE's patents. Life Technologies filed the lawsuit against ILMN in 2009. The Court ruled that, “Life Tech cannot establish, as a matter of law, that the accused Illumina systems infringe” the patents. ILMN +1.4% AH.
    | Comment!
  • Jan. 18, 2013, 9:01 AM
    Life Technologies (LIFE) +13.5% premarket after the board hires Deutsche Bank and Moelis to assist in its annual strategic review. Chatter on pricing in an LBO has been in the $65-$75 range, but Jefferies says this is overly ambitious, and $50-$60 is more likely. Is Roche (RHHBY.PK) interested after Illumina has fallen through?
    | Comment!
  • Jan. 7, 2013, 4:03 PM
    Sequenom (SQNM -2.3%) goes into the close a bit stronger than it started out the day, recovering some of its earlier 6% dip on some upbeat preliminary FY12 guidance posted over the weekend. The company said that it is expecting revenues of $89M, equating to a Y/Y growth rate of 59%, but the results were largely overshadowed by Illumina's (ILMN -7.3%) acquisition of Verinata, whose competing verifi test - which analyzes fetal DNA naturally found in a pregnant women's blood to look for missing or extra copies of chromosomes - carry's less risk than Sequenom’s SEQureDx technology.
Visit Seeking Alpha's
ILMN vs. ETF Alternatives
Company Description
Illumina Inc providessequencing-and array-based solutions for genetic analysis. Itsproducts enabled researchers to explore DNA, helping them create the first map of gene variations associated with health, disease, and drug response.
Sector: Healthcare
Industry: Biotechnology
Country: United States